HOLDING STRONG!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Fatty food fix....
Could be a relatively easy fix. Below is from label for Oxecta related to food effect-
When administered with a high fat meal, mean AUC values are increased by 21% and peak concentrations are decreased by 14%. Food causes a delay in Tmax from 1.25 to 3.00 hours. These changes in oxycodone pharmacokinetics are not considered clinically relevant; therefore, OXECTA can be taken without regard to food.
Elite may already have the data and just need to update the label based on fatty food effects and oxycodone.
A CRL contains info on what needs to be done to get acceptance. Smart companies schedule meetings with FDA to discuss path forward and obtain clarifications if needed. Elite is probably working it already.
Read the regs on CRLs and you will see what they contain.
Reasons for CRL Title 21 ? Chapter I ? Subchapter D ? Part 314 ? Subpart D ? §314.125
Title 21: Food and Drugs
PART 314—APPLICATIONS FOR FDA APPROVAL TO MARKET A NEW DRUG
Subpart D—FDA Action on Applications and Abbreviated Applications
§314.125 Refusal to approve an application.
(a) The Food and Drug Administration will refuse to approve the application and for a new drug give the applicant written notice of an opportunity for a hearing under §314.200 on the question of whether there are grounds for denying approval of the application under section 505(d) of the act, if:
(1) FDA sends the applicant a complete response letter under §314.110;
(2) The applicant requests an opportunity for hearing for a new drug on the question of whether the application is approvable; and
(3) FDA finds that any of the reasons given in paragraph (b) of this section apply.
(b) FDA may refuse to approve an application for any of the following reasons:
(1) The methods to be used in, and the facilities and controls used for, the manufacture, processing, packing, or holding of the drug substance or the drug product are inadequate to preserve its identity, strength, quality, purity, stability, and bioavailability.
(2) The investigations required under section 505(b) of the act do not include adequate tests by all methods reasonably applicable to show whether or not the drug is safe for use under the conditions prescribed, recommended, or suggested in its proposed labeling.
(3) The results of the tests show that the drug is unsafe for use under the conditions prescribed, recommended, or suggested in its proposed labeling or the results do not show that the drug product is safe for use under those conditions.
(4) There is insufficient information about the drug to determine whether the product is safe for use under the conditions prescribed, recommended, or suggested in its proposed labeling.
(5) There is a lack of substantial evidence consisting of adequate and well-controlled investigations, as defined in §314.126, that the drug product will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested in its proposed labeling.
(6) The proposed labeling is false or misleading in any particular.
(7) The application contains an untrue statement of a material fact.
(8) The drug product's proposed labeling does not comply with the requirements for labels and labeling in part 201.
(9) The application does not contain bioavailability or bioequivalence data required under part 320 of this chapter.
(10) A reason given in a letter refusing to file the application under §314.101(d), if the deficiency is not corrected.
(11) The drug will be manufactured or processed in whole or in part in an establishment that is not registered and not exempt from registration under section 510 of the act and part 207.
(12) The applicant does not permit a properly authorized officer or employee of the Department of Health and Human Services an adequate opportunity to inspect the facilities, controls, and any records relevant to the application.
(13) The methods to be used in, and the facilities and controls used for, the manufacture, processing, packing, or holding of the drug substance or the drug product do not comply with the current good manufacturing practice regulations in parts 210 and 211.
(14) The application does not contain an explanation of the omission of a report of any investigation of the drug product sponsored by the applicant, or an explanation of the omission of other information about the drug pertinent to an evaluation of the application that is received or otherwise obtained by the applicant from any source.
(15) A nonclinical laboratory study that is described in the application and that is essential to show that the drug is safe for use under the conditions prescribed, recommended, or suggested in its proposed labeling was not conducted in compliance with the good laboratory practice regulations in part 58 of this chapter and no reason for the noncompliance is provided or, if it is, the differences between the practices used in conducting the study and the good laboratory practice regulations do not support the validity of the study.
(16) Any clinical investigation involving human subjects described in the application, subject to the institutional review board regulations in part 56 of this chapter or informed consent regulations in part 50 of this chapter, was not conducted in compliance with those regulations such that the rights or safety of human subjects were not adequately protected.
(17) The applicant or contract research organization that conducted a bioavailability or bioequivalence study described in §320.38 or §320.63 of this chapter that is contained in the application refuses to permit an inspection of facilities or records relevant to the study by a properly authorized officer or employee of the Department of Health and Human Services or refuses to submit reserve samples of the drug products used in the study when requested by FDA.
(18) For a new drug, the application failed to contain the patent information required by section 505(b)(1) of the act.
(c) For drugs intended to treat life-threatening or severely-debilitating illnesses that are developed in accordance with §§312.80 through 312.88 of this chapter, the criteria contained in paragraphs (b) (3), (4), and (5) of this section shall be applied according to the considerations contained in §312.84 of this chapter.
CRL according to TITLE 21--FOOD AND DRUGS
CHAPTER I--FOOD AND DRUG ADMINISTRATION
DEPARTMENT OF HEALTH AND HUMAN SERVICES
SUBCHAPTER D--DRUGS FOR HUMAN USE
PART 314 -- APPLICATIONS FOR FDA APPROVAL TO MARKET A NEW DRUG
Subpart D--FDA Action on Applications and Abbreviated Applications
Sec. 314.110 Complete response letter to the applicant.
(a) Complete response letter. FDA will send the applicant a complete response letter if the agency determines that we will not approve the application or abbreviated application in its present form for one or more of the reasons given in 314.125 or 314.127, respectively.
(1) Description of specific deficiencies. A complete response letter will describe all of the specific deficiencies that the agency has identified in an application or abbreviated application, except as stated in paragraph (a)(3) of this section.
(2) Complete review of data. A complete response letter reflects FDA's complete review of the data submitted in an original application or abbreviated application (or, where appropriate, a resubmission) and any amendments that the agency has reviewed. The complete response letter will identify any amendments that the agency has not yet reviewed.
(3) Inadequate data. If FDA determines, after an application is filed or an abbreviated application is received, that the data submitted are inadequate to support approval, the agency might issue a complete response letter without first conducting required inspections and/or reviewing proposed product labeling.
(4) Recommendation of actions for approval. When possible, a complete response letter will recommend actions that the applicant might take to place the application or abbreviated application in condition for approval.
(b) Applicant actions. After receiving a complete response letter, the applicant must take one of following actions:
(1) Resubmission. Resubmit the application or abbreviated application, addressing all deficiencies identified in the complete response letter.
(i) A resubmission of an application or efficacy supplement that FDA classifies as a Class 1 resubmission constitutes an agreement by the applicant to start a new 2-month review cycle beginning on the date FDA receives the resubmission.
(ii) A resubmission of an application or efficacy supplement that FDA classifies as a Class 2 resubmission constitutes an agreement by the applicant to start a new 6-month review cycle beginning on the date FDA receives the resubmission.
(iii) A resubmission of an NDA supplement other than an efficacy supplement constitutes an agreement by the applicant to start a new review cycle the same length as the initial review cycle for the supplement (excluding any extension due to a major amendment of the initial supplement), beginning on the date FDA receives the resubmission.
(iv) A major resubmission of an abbreviated application constitutes an agreement by the applicant to start a new 6-month review cycle beginning on the date FDA receives the resubmission.
(v) A minor resubmission of an abbreviated application constitutes an agreement by the applicant to start a new review cycle beginning on the date FDA receives the resubmission.
(2) Withdrawal. Withdraw the application or abbreviated application. A decision to withdraw an application or abbreviated application is without prejudice to a subsequent submission.
(3) Request opportunity for hearing. Ask the agency to provide the applicant an opportunity for a hearing on the question of whether there are grounds for denying approval of the application or abbreviated application under section 505(d) or (j)(4) of the act, respectively. The applicant must submit the request to the Associate Director for Policy, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, MD 20993. Within 60 days of the date of the request for an opportunity for a hearing, or within a different time period to which FDA and the applicant agree, the agency will either approve the application or abbreviated application under 314.105, or refuse to approve the application under 314.125 or abbreviated application under 314.127 and give the applicant written notice of an opportunity for a hearing under 314.200 and section 505(c)(1)(B) or (j)(5)(c) of the act on the question of whether there are grounds for denying approval of the application or abbreviated application under section 505(d) or (j)(4) of the act, respectively.
(c) Failure to take action. (1) An applicant agrees to extend the review period under section 505(c)(1) or (j)(5)(A) of the act until it takes any of the actions listed in paragraph (b) of this section. For an application or abbreviated application, FDA may consider an applicant's failure to take any of such actions within 1 year after issuance of a complete response letter to be a request by the applicant to withdraw the application, unless the applicant has requested an extension of time in which to resubmit the application. FDA will grant any reasonable request for such an extension. FDA may consider an applicant's failure to resubmit the application within the extended time period or to request an additional extension to be a request by the applicant to withdraw the application.
(2) If FDA considers an applicant's failure to take action in accordance with paragraph (c)(1) of this section to be a request to withdraw the application, the agency will notify the applicant in writing. The applicant will have 30 days from the date of the notification to explain why the application should not be withdrawn and to request an extension of time in which to resubmit the application. FDA will grant any reasonable request for an extension. If the applicant does not respond to the notification within 30 days, the application will be deemed to be withdrawn.
As it stands now we do not know what was in the CRL.... It could be something small that may be easy to fix or it may be something big that could take longer. It is up to ELITE whether they want to tell us as CRLs are not made public unless the company discloses what is in the letter.
TITLE 21--FOOD AND DRUGS
CHAPTER I--FOOD AND DRUG ADMINISTRATION
DEPARTMENT OF HEALTH AND HUMAN SERVICES
SUBCHAPTER D--DRUGS FOR HUMAN USE
PART 314 -- APPLICATIONS FOR FDA APPROVAL TO MARKET A NEW DRUG
Subpart D--FDA Action on Applications and Abbreviated Applications
Sec. 314.110 Complete response letter to the applicant.
(a) Complete response letter. FDA will send the applicant a complete response letter if the agency determines that we will not approve the application or abbreviated application in its present form for one or more of the reasons given in 314.125 or 314.127, respectively.
(1) Description of specific deficiencies. A complete response letter will describe all of the specific deficiencies that the agency has identified in an application or abbreviated application, except as stated in paragraph (a)(3) of this section.
(2) Complete review of data. A complete response letter reflects FDA's complete review of the data submitted in an original application or abbreviated application (or, where appropriate, a resubmission) and any amendments that the agency has reviewed. The complete response letter will identify any amendments that the agency has not yet reviewed.
(3) Inadequate data. If FDA determines, after an application is filed or an abbreviated application is received, that the data submitted are inadequate to support approval, the agency might issue a complete response letter without first conducting required inspections and/or reviewing proposed product labeling.
(4) Recommendation of actions for approval. When possible, a complete response letter will recommend actions that the applicant might take to place the application or abbreviated application in condition for approval.
(b) Applicant actions. After receiving a complete response letter, the applicant must take one of following actions:
(1) Resubmission. Resubmit the application or abbreviated application, addressing all deficiencies identified in the complete response letter.
(i) A resubmission of an application or efficacy supplement that FDA classifies as a Class 1 resubmission constitutes an agreement by the applicant to start a new 2-month review cycle beginning on the date FDA receives the resubmission.
(ii) A resubmission of an application or efficacy supplement that FDA classifies as a Class 2 resubmission constitutes an agreement by the applicant to start a new 6-month review cycle beginning on the date FDA receives the resubmission.
(iii) A resubmission of an NDA supplement other than an efficacy supplement constitutes an agreement by the applicant to start a new review cycle the same length as the initial review cycle for the supplement (excluding any extension due to a major amendment of the initial supplement), beginning on the date FDA receives the resubmission.
(iv) A major resubmission of an abbreviated application constitutes an agreement by the applicant to start a new 6-month review cycle beginning on the date FDA receives the resubmission.
(v) A minor resubmission of an abbreviated application constitutes an agreement by the applicant to start a new review cycle beginning on the date FDA receives the resubmission.
(2) Withdrawal. Withdraw the application or abbreviated application. A decision to withdraw an application or abbreviated application is without prejudice to a subsequent submission.
(3) Request opportunity for hearing. Ask the agency to provide the applicant an opportunity for a hearing on the question of whether there are grounds for denying approval of the application or abbreviated application under section 505(d) or (j)(4) of the act, respectively. The applicant must submit the request to the Associate Director for Policy, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, MD 20993. Within 60 days of the date of the request for an opportunity for a hearing, or within a different time period to which FDA and the applicant agree, the agency will either approve the application or abbreviated application under 314.105, or refuse to approve the application under 314.125 or abbreviated application under 314.127 and give the applicant written notice of an opportunity for a hearing under 314.200 and section 505(c)(1)(B) or (j)(5)(c) of the act on the question of whether there are grounds for denying approval of the application or abbreviated application under section 505(d) or (j)(4) of the act, respectively.
(c) Failure to take action. (1) An applicant agrees to extend the review period under section 505(c)(1) or (j)(5)(A) of the act until it takes any of the actions listed in paragraph (b) of this section. For an application or abbreviated application, FDA may consider an applicant's failure to take any of such actions within 1 year after issuance of a complete response letter to be a request by the applicant to withdraw the application, unless the applicant has requested an extension of time in which to resubmit the application. FDA will grant any reasonable request for such an extension. FDA may consider an applicant's failure to resubmit the application within the extended time period or to request an additional extension to be a request by the applicant to withdraw the application.
(2) If FDA considers an applicant's failure to take action in accordance with paragraph (c)(1) of this section to be a request to withdraw the application, the agency will notify the applicant in writing. The applicant will have 30 days from the date of the notification to explain why the application should not be withdrawn and to request an extension of time in which to resubmit the application. FDA will grant any reasonable request for an extension. If the applicant does not respond to the notification within 30 days, the application will be deemed to be withdrawn.
News day after FDA approval.... so I did a search looking at FDA approvals on their site and then google news search for the related drug/company. From what I saw in most cases the news date was the day after the drug approval date as indicated on the FDA website.
With that being said we may not see a PR until Saturday or Monday if SequestOx shows on the FDA site today.
ELTP broke through the resistance level of $0.3517. Currently above all key turning points!
$0.38 is next significant resistance point (4/13 week high) and then the resistance of the 52 week high at $0.443
Moving on UP!
Just 12 trading days, but approval could come before 14 July!
NASDAQ short sale files
What you need to know:
•On Monday, August 3, 2009, NASDAQ OMX introduced new Daily Short Sale Volume and Monthly Short Sale Transaction files for The NASDAQ Stock Market and NASDAQ OMX BX.
•The new Short Sale files will enable investors and traders to see the level of short sale activity in the NASDAQ and NASDAQ OMX BX markets for NASDAQ-, NYSE- and regional exchange-listed securities.
•NASDAQ OMX believes that the new files will foster better market transparency and help to bolster investor confidence in the U.S. securities markets.
------------------------------------------------------------------
What data is included in the NASDAQ OMX Short Sale Volume and Transaction files?
NASDAQ OMXSM will release two types of short sale files based on the trading activity on The NASDAQ Stock Market® and NASDAQ OMX BXSM (BXSM):
•The Daily Short Sale Volume Files will reflect the aggregated number of shares executed on NASDAQ® and BX during regular trading hours. At the security level, NASDAQ OMX will show the volume for executed short sale trades as well as the total trading volume for both NASDAQ and BX. Because NASDAQ and BX market participants may trade all U.S. exchange-listed securities, the file will include short sale data for NASDAQ-, NYSE- and regional exchange-listed issues.
•The Monthly Short Sale Transaction File will provide a trade-by-trade record of all short sales executed on the NASDAQ and BX execution systems and reported to a consolidated tape in NASDAQ-, NYSE- and Amex-listed issues. Within this file, NASDAQ OMX will provide trade details including the transaction time, price and number of share for every short sale transaction.
For each file type, NASDAQ OMX will post a separate file for the NASDAQ and BX markets.
For details on file formats, please refer to the technical specifications on the NASDAQ OMX Trader® website.
Why is NASDAQ OMX posting these files?
NASDAQ OMX is responding to a request from the Securities and Exchange Commission (SEC) to increase the transparency of short sale activity in the U.S. marketplace. NASDAQ OMX agrees that the short sale files will promote increased transparency and bolster investor confidence in the markets.
Is there a charge for the files?
Until there is an SEC approved fee, NASDAQ OMX will be posting the data files on the public NASDAQ OMX Trader website FTP server.
When will the files be available?
NASDAQ OMX will begin to generate the Daily Short Sale Volume Files on Monday, August 3, 2009, for both NASDAQ and BX. The Daily Short Sale Files will be posted to the NASDAQ OMX Trader website FTP server at approximately 5:00 p.m., Eastern Time (ET). Firms are advised to set up FTP processing to pull the data files at one-half hour intervals from 5:00 p.m. ET to 6:30 p.m. ET.
NASDAQ OMX will generate the Monthly Short Sale Transaction Files for the NASDAQ and BX markets on the last trading day of each month beginning in August. The Monthly Short Sale File will reflect the trading volume for the previous trading month. For example, the first file, which will be posted August 31, 2009, will include the trade details for July of 2009.
Where will the short sale files be posted?
Upon initial release, the NASDAQ OMX Short Sale Files will be posted to the public NASDAQ OMX Trader website FTP site. For details on the Short Sale File formats, please refer to the technical specifications on the NASDAQ OMX Trader website.
How do the Short Sale Files differ from the existing NASDAQ Short Interest Report?
The Short Interest Report is produced on a semimonthly basis and includes a summary of the consolidated market short interest positions in all NASDAQ-listed securities. This information is reported by market participants and is therefore an accurate reflection of the total short interest positions held on a per-security basis. Please see the Short Interest Report product page on the NASDAQ OMX Trader website as well as the enclosed Short Sale and Short Interest Comparison document further highlighting differences between the data reports.
ELTP 10:04:24 0.34602 10000 trade showing on time&sales. So how is it that I cannot trade in the 1/10,000ths or 1/100,000ths of a penny and we see these type of trades all day long??
Thanks Rebel13, filed SEC TCR complaints = action!
AND YES, please send your reports to the NY AG! The more eyes we have watching the manipulation the better!
Watch ELTP trading and file SEC TCR complaints!
Multiple reports have already been filed and TCR #s received. Not just mine :)
You can select "Manipulation of a security" and "abusive naked short selling" or whatever you want to report in your complaint and give details of what you see or experience:
*order not getting filled when your price is below the ask price
*multiple trades at 0.XXXXXX (indicates illegal high frequency/computer programmed manipulative trading)
*sell volume exceeding buy volume daily
*abnormal volume/price swings on NO news
*crashing price in last hour of trading
However you want to report it JUST FILE A COMPLAINT!!!!!!!!
google - SEC Tips, Complaints and Referrals website - and file your complaint ASAP!
MORE COMPLAINTS = MORE ACTION!!!!!!!!
Come on, at least try fighting for fair trading of ELPT
MORE COMPLAINTS = MORE ACTION!!!!!!!!
Watch trading and file SEC TCR complaints! Especially this week.
Multiple reports have already been filed and TCR #s received. Not just mine :)
You can select "Manipulation of a security" and "abusive naked short selling" or whatever you want to report in your complaint and give details of what you see - sell volume exceeding buy volume daily, abnormal volume/price swings on NO news, crashing price in last hour of trading - however you want to report it JUST FILE A COMPLAINT!!!!!!!!
google - SEC Tips, Complaints and Referrals website - and file your complaint ASAP!
MORE COMPLAINTS = MORE ACTION!!!!!!!!
Come on, at least try fighting for fair trading of ELPT
MORE COMPLAINTS = MORE ACTION!!!!!!!!
PR CC Monday, release Annual report Tuesday, CC on Wednesday??
When do you think it will all happen this week??
Starting a list of SEC TCR Reference Numbers for illegal trading of ELTP!
google - SEC Tips, Complaints and Referrals website - and file your complaint ASAP!
MORE COMPLAINTS = MORE ACTION!!!!!!!!
PLEASE file your complaints, draw attention to the manipulation of Elite Pharmaceuticals! You can select "Manipulation of a security" and "abusive naked short selling" or any other categories you think is more appropriate on the TCR form.
File your report and give details of what you see - sell volume exceeding buy volume daily, abnormal volume/price swings on NO news, crashing price in last hour of trading - however you want to report it JUST FILE A COMPLAINT!!!!!!!!
At least try, fight for fair trading of ELPT!
MORE COMPLAINTS = MORE ACTION!!!!!!!!
Way to go Doc Ninja! Keep the TCRs coming TEAM!
[Probably true. When 3 million shares trade close to ten times recent volume with most of the trades Green and the asked is toppled by a 2500 share "sale" makes you want to call the SEC. lol]
toofun,
that is exactly part of the TCR complaint that I filed!
SEC does investigate naked short selling!
It is a selection for your category of complaint.
SEC compliant FILED!!!!!!!!
TCR Submitted Successfully - Reference Number: TCR1465578392037
I will file complaints daily or more often to draw SEC attention to the trading of ELTP. The manipulation this week is outrageous! I will file complaints daily so that they are watching next week when ELTP reports annual results and through the next month leading up to the FDA decision.
PLEASE file your complaints as well! You can select "Manipulation of a security" on your report and give details of what you see - sell volume exceeding buy volume daily, abnormal volume/price swings on NO news, crashing price in last hour of trading - however you want to report it JUST FILE A COMPLAINT!!!!!!!!
Link: https://denebleo.sec.gov/TCRExternal/index.xhtml
MORE COMPLAINTS = MORE ACTION!!!!!!!!
Yes, it really happens!
Think about it. Many trading companies/funds trade on computer based tracking that looks for signals. Many retail and amateur traders use basic programs or subscribe to websites that track and provide trade indicators or signals. ELTP's chart was set with the bands tight and signals start to indicate a major BUY signal!
So, MM's or a major fund jacked the chart and signals so it would be a little easier to control the run when ELTP reports next week or when the FDA approval comes!
MMs jacked the buy/sale indicators!
The run up/down was pure manipulation that totally messed up the buy/sell signals and short term buy/sell chart indicators.
Barchart opinion went from all BUY-Green to a mix/mash of buy/sell/hold and Americanbulls went to a sell signal. A lot of people follow these so they jacked the charts when NOTHING has change! They had to do this before the ELTP financial report next week and the eminent FDA approval so they could try to limit the number of people watching. LOL, the games they play!
Eugene Pfeifer - FTC regulatory and TRADE matters!
Thx for the presentation Couch! FANTASTIC!!!!!!!!
This stood out to me "FTC related regulatory and trade matters". TRADE matters!!!! Elite's potential for global market. Could there be links with the EPIC purchase and the potential for foreign markets for ELI-200 or the generic pipeline or the future pipeline??
Had to share! LOL! Must read! Do not drink while reading, blew water through my nose on this one.
From board on yahoo.
jim_morison12345 • 10 hours ago
With drug prices being scrutinized on a national scale during this political season, I wonder how that will affect future revenues and projections for our drugs. Doesn't seem to bode well.
. .
2 Replies to jim_morison12345
rooster_tails • 9 hours ago
I wonder if the price of eggs is worth the wear and tear on the chickens ahss, that doesn't bode well either yet everyone keeps buying eggs.
meifud • 5 hours ago Flag
our chickens lay super jumbo size eggs, and if they didn't each lay one every day i fear some might explode in the coop in the middle of the night
as for jimbo's concern about drug pricing being a political football, that is something that comes with the territory but capitalism should ensure that needed drugs will always have a profit margin, and Hakim has already demonstrated amazingly low cost of production with the generic line, so Elite should fare better than most others regardless of what happens L
QTR report and CC Tuesday or Wednesday next week.
Should be a great report. Income from generics and another milestone payment for submitting/FDA acceptance of NDA.
PR for Elite's quarterly report!
Should see a PR tomorrow announcing day of quarterly report and CC.
Elite usually has an additional PR with some company developments along with the QTR PR, will we get one??
CC should be next Tuesday.
Elite info from a Canadian site??
Link-
http://cobrands.morningstar.ca/ProfileService/report/pdf/7AVeC9IEuZ/en-CA/0P000005VC/ST/Quote
Look at page 5 and go down the list. Elite is there but the stats are a little different from the stats on Yahoo Finance "key statistics".
It shows the operating margin a lot lower than yahoo finance. Also P/S is a little higher.
page was dated today. Interesting.
Yesterdays daily short volume for ELTP.
Date|Symbol|ShortVolume|ShortExemptVolume|TotalVolume|Market
20160425|ELTP|599296|0|1524551|O
So it can be easily seen that there was much less shorting than usual yesterday. Usually when ELTP has good volume the short % is around 50 or higher.
As one said that buying was easily absorbed but if you were watching close the shorts continued their long term objective of suppressing the stock. Shorts were selling to the major short player that was covering. Haha, told you to watch the signals!
Like I said, what did you expect that they would cover in one day, LOL, causing huge volume that draws attention and a price run where they cannot cover in the current range.
Right before your eyes and the shorts still cannot see!
Shorts, notice the volume today. You cannot even see it. For weeks we have be around 200K to 500K shares traded and today 1.5M shares traded. I tried to tell you a major player was covering soon! These shorts cannot comprehend.... this player is one of the best and will let the amateur shorts burn. What did you expect that they would cover all at once, haha. That would be volume in the 10s of millions and this player knows how to work the amateur shorts to keep the price steady while this player covers. One big trade and then smaller ones throughout the day. While others are trying to figure out why there was just one big trade this player has covered a nice chunk. This short player will also take advantage of other small time shorts trying to influence the price and cover as they short to this player. When this player has covered then I expect a change to the buy leading into July and at any time there could be a significant run started that will generate margin calls to the amateur shorts as they watch their trading accounts turn negative by $10s to $100s of thousands.
LOL, they cannot even see it coming! It is right in front of you.
Told you to watch the signals.
LOL, like I said Ackman will love this story about how the shorts could not see one of their own making $$million off of them.
Shorts, told you a major player was going to cover. You cannot even see it.
There are short positions in ELTP.
Reminder to John....careful, big player to cover!
Market makers (MM)are -
CDEL 0.325 3030 04/22
ATDF 0.324 10000 04/22
CSTI 0.322 50000 04/22
ETRF 0.322 2500 04/22
NITE 0.3185 2500 04/22
this shows them active on the bid.... go look at Level II to see the ask side.
Now, is it possible for these MMs to short whether legal or illegal (i.e., naked). I would have to say Yes!
Search Citadel (CDEL) and you find things like -
http://www.valuewalk.com/2015/08/citadel-china/
Search Automated Trading Desk and you find things like (hmm, talks about dark pools also) -
http://wallstreetonparade.com/2014/06/citigroup%E2%80%99s-dark-pools-here%E2%80%99s-why-the-public-doesn%E2%80%99t-trust-wall-street/
Search G1 Execution Services (ETRF) and you find things like -
http://www.shearman.com/~/media/Files/NewsInsights/Publications/2015/01/Securities-Enforcement-2014-Year-End-Review-LT-012915.pdf
Search Knight Equity Markets and you find things like -
http://www.bloombergview.com/articles/2015-12-01/naked-shorts-at-the-supreme-court
You do word searches in each article for the respect MMs but you get the picture.
Keep your short position if you want but keep in mind........ shorts are ruthless people with no morals so if you think the big player that is about to cover has any care for his brother shorts, LOL, keep right on thinking that, LOL!
When it comes to money, everybody/anybody will stab you in the back and let you bleed out while they take the money for themselves.
It is coming.... tried to let you know.... am I a long? am I a flipper, am I a short? Nobody knows on these boards. Haha, tried to give you a heads up.... listen or get left behind.
ELTP will start rising!
As with all false short attacks, the share price of ELTP will bounce back. I expect the shorts to continue their rumor mongering so they can continue buying to cover their shorts as the share price rises back up however they are tight schedule now with the FDA potential approval of SequestOx arriving by 14 July 2015 or sooner it will become increasingly more difficult to cover at lower prices. And if a major BIG short decides to cover on their own and leaves their other short buddies to go bankrupt then it will be a winning day for justice. (Hint to shorts - major player covering short position soon, VERY soon! Believe it or not :) , you choose and see who gets left out swinging in the wind.)
There is a lot methods for manipulation by shorts to control a stock over long periods of time - First information is widely distributed to make investors wonder about the company and to put fear into those longs that hold the stock. Next, high volume shorting takes place to drive the company's share price down. As the short attack continues, more people parade out news to continue to put questions in the back of investors' minds. On a daily basis, shorts use computerized trading to control the direction of the share price. At opportune times, the shorts overwhelm the buyers (bid price) of the stock by selling short large number of shares to drive the share price down and to eliminate the buyers for the stock at that given time. Shorts need to control the stock's share price over a long time (often several months to well over a year), and can't afford to just accumulate an unlimited number of short positions in the stock, so they have to be buying shares at the same time they are selling shares too. When the shorts drive the share price down, eliminating buyers as discussed above, some of those investors trying to sell their shares at that same time will follow the share price activity downward lowering their ask price. Now the shorts can buy back some of the shares they have shorted at lower prices including some shares where longs have put stop-loss sale orders to protect against downside losses. The shorts will only buy shares part of the way back up as the share price rises, and then wait to see if new buyers come into the market. If the share price continues to rise up to much again during the day, the shorts will repeat the same selling and buying process to control the share price. As mentioned above, the shorts need to control the share price over an extended period of time. They need to wear down the longs with rumor mongering as well as by creating fear as the longs continue to see the share price go down from the computerized trading. They hope the longs will give up and sell their shares at the lowest possible share price.
NOW :)If one or more of the major short players decided they didn't want to participate further in driving the share price down, and decided to buy to cover, this would create a major problem for those other major short players. The remaining major short players would not only have to drive the price down based on selling shares to new longs but would also have to sell shares to those other major short players buying to cover their shorts. The remaining short players would not be able to manipulate the stock share price as easy as they did working together. As this cycle continues, eventually the shorts would lose control and the stock begin a sustain rise in price per share as the short continue to try manipulate the rise and limit their losses. However, if the company has substantial news or very positive business results and SEC filings then the shorts could lose control completely as the stock price sky rockets. Then you will see something absurdly entertaining, or woefully tragic, depending on one's perspective, like that one trader, Joe Campbell, that was on the wrong side, the short side of a massive surge. The "dummy" E-trader, Joe Campbell, decided to go $35,000 short KBIO "and now owes $ETFC a wonderful $106K and was begging for help on GoFundMe. I believe he had to borrow against his and his wife 401K to cover his huge short mistake.
JMHO!
ELTP PR for quarterly report in about 11 days and then the CC should be around 10 May 2016. Could there be a major PR coming in the next week? ELTP usually does something interesting right before the quarterly report.
Then we should see FDA approval for ELI-200 in about 2 months. Good times ahead!
ELTP longs desperate.... I do not think so! Longs are set and holding. Could be that flippers or shorts are trying to trigger a play to get some volume back in ELTP so they can make some burger money or get some shares trading so they can cover. You do not know and I do not know. Such is the way of the market now days.
Just know that a major player will be covering soon :)
Ackman will love this story, LOL! JMO :)
Yes John, there are short positions in ELTP.
Market makers (MM)are -
CDEL 0.325 3030 04/22
ATDF 0.324 10000 04/22
CSTI 0.322 50000 04/22
ETRF 0.322 2500 04/22
NITE 0.3185 2500 04/22
this shows them active on the bid.... go look at Level II to see the ask side.
Now, is it possible for these MMs to short whether legal or illegal (i.e., naked). I would have to say Yes!
Search Citadel (CDEL) and you find things like -
http://www.valuewalk.com/2015/08/citadel-china/
Search Automated Trading Desk and you find things like (hmm, talks about dark pools also) -
http://wallstreetonparade.com/2014/06/citigroup%E2%80%99s-dark-pools-here%E2%80%99s-why-the-public-doesn%E2%80%99t-trust-wall-street/
Search G1 Execution Services (ETRF) and you find things like -
http://www.shearman.com/~/media/Files/NewsInsights/Publications/2015/01/Securities-Enforcement-2014-Year-End-Review-LT-012915.pdf
Search Knight Equity Markets and you find things like -
http://www.bloombergview.com/articles/2015-12-01/naked-shorts-at-the-supreme-court
You do word searches in each article for the respect MMs but you get the picture.
Keep your short position if you want but keep in mind........ shorts are ruthless people with no morals so if you think the big player that is about to cover has any care for his brother shorts, LOL, keep right on thinking that, LOL!
When it comes to money, everybody/anybody will stab you in the back and let you bleed out while they take the money for themselves.
It is coming.... tried to let you know.... am I a long? am I a flipper, am I a short? Nobody knows on these boards. Haha, tried to give you a heads up.... listen or get left behind.
Jules, yes, some have been shorting since ELTP was on AMEX.
Heard a rumor and had a friend do some backdoor snooping. Big player looking cover a long term short. Cannot get into details but it is going to happen soon from what I understand. Will be interesting to see how it plays out :)
Watch your market makers NITE, DOMS, ETFC, FANC!
Shorts watch your market makers for signals! Major market maker covering soon! Don't get left out!
Who is covering........Auriga Global Investors, Harvest Capital Strategies LLC, J.P. Morgan Investment Management Inc, Omega Advisors Inc, Sabby Management LLC, War Chest Capital Partners LLC, could be firms that would cover. Do your research to see who your short partners are and do not get left behind when they cover.
Just trying to help....... do not want to see you on "GoFundMe" begging!
ELTP will bounce back!
As with all false short attacks, the share price of ELTP will bounce back. I expect the shorts to continue their rumor mongering so they can continue buying to cover their shorts as the share price rises back up however they are tight schedule now with the FDA potential approval of SequestOx arriving by 14 July 2015 or sooner it will become increasingly more difficult to cover at lower prices. And if a major BIG short decides to cover on their own and leaves their other short buddies to go bankrupt then it will be a winning day for justice. (Hint to shorts - major player covering short position soon, VERY soon! Believe it or not :) , you choose and see who gets left out swinging in the wind.)
There is a lot methods for manipulation by shorts to control a stock over long periods of time - First information is widely distributed to make investors wonder about the company and to put fear into those longs that hold the stock. Next, high volume shorting takes place to drive the company's share price down. As the short attack continues, more people parade out news to continue to put questions in the back of investors' minds. On a daily basis, shorts use computerized trading to control the direction of the share price. At opportune times, the shorts overwhelm the buyers (bid price) of the stock by selling short large number of shares to drive the share price down and to eliminate the buyers for the stock at that given time. Shorts need to control the stock's share price over a long time (often several months to well over a year), and can't afford to just accumulate an unlimited number of short positions in the stock, so they have to be buying shares at the same time they are selling shares too. When the shorts drive the share price down, eliminating buyers as discussed above, some of those investors trying to sell their shares at that same time will follow the share price activity downward lowering their ask price. Now the shorts can buy back some of the shares they have shorted at lower prices including some shares where longs have put stop-loss sale orders to protect against downside losses. The shorts will only buy shares part of the way back up as the share price rises, and then wait to see if new buyers come into the market. If the share price continues to rise up to much again during the day, the shorts will repeat the same selling and buying process to control the share price. As mentioned above, the shorts need to control the share price over an extended period of time. They need to wear down the longs with rumor mongering as well as by creating fear as the longs continue to see the share price go down from the computerized trading. They hope the longs will give up and sell their shares at the lowest possible share price.
NOW :)If one or more of the major short players decided they didn't want to participate further in driving the share price down, and decided to buy to cover, this would create a major problem for those other major short players. The remaining major short players would not only have to drive the price down based on selling shares to new longs but would also have to sell shares to those other major short players buying to cover their shorts. The remaining short players would not be able to manipulate the stock share price as easy as they did working together. As this cycle continues, eventually the shorts would lose control and the stock begin a sustain rise in price per share as the short continue to try manipulate the rise and limit their losses. However, if the company has substantial news or very positive business results and SEC filings then the shorts could lose control completely as the stock price sky rockets. Then you will see something absurdly entertaining, or woefully tragic, depending on one's perspective, like that one trader, Joe Campbell, that was on the wrong side, the short side of a massive surge. The "dummy" E-trader, Joe Campbell, decided to go $35,000 short KBIO "and now owes $ETFC a wonderful $106K and was begging for help on GoFundMe. I believe he had to borrow against his and his wife 401K to cover his huge short mistake.
JMHO!
ELTP quarterly report in about one month and then about 30-60 days after that we should see FDA approval for ELI-200. Good times ahead!
I believe once SequestOX (ELI-200)is approved we really start to see things moving with Elite. I think they are looking for this to provide verification of their technology and then the door is wide open for them and us.
LOL, Elite may be a potential acquisition of a foreign company because -
I was just reading over various news with topics such as election, recession, trade deals, etc... and it dawned on me that we could see a rush of foreign purchases of American companies prior to the next president taking office due to-
1) They do not know what will happen with trade deals or foreign taxes if Trump is in office.
2) They do not want to pay Bill Clinton huge public speaking fees to do business in the USA.
or
3) They think everything will just lockup completely if Cruz gets it.
HAHA, just having little fun.